YungKhai
2021-06-30

$Histogenics(OCGN)$

Moving another step closer to World Health Organisation (WHO) approval, the rolling data of ‘made in India’ Covid-19 vaccine Covaxin will be starting in July. This has come after the pre-submission meeting held on June 23 with Bharat Biotech.

The status of Covid-19 vaccines within the EUL/PQ (emergency use listing/prequalification) evaluation process was updated on Tuesday by WHO in its latest guidance document.

Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, WHO guidelines said.

Stating that its Covid-19 vaccine Covaxin adheres to international standards, Bharat Biotech’s joint managing director Suchitra Ella on Tuesday said external timelines are in the company’s hands.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
2